Latest Pharma Insights
How Abu Dhabi Is Racing To Set The Gulf’s Fertility Benchmark With Screening And Diagnosis
Abu Dhabi has set a 2030 roadmap to achieve ambitious global reproductive health ecosystem goals. Prevention and preconception health, genetic screening, fertility diagnosis and treatment and IVF are central elements. L.E.K. Consulting explained how Abu Dhabi is differentiating in its approach.
In Vivo - September 29, 2026
Abu Dhabi has set a 2030 roadmap to achieve ambitious global reproductive health ecosystem goals. Prevention and preconception health, genetic screening, fertility diagnosis and treatment and IVF are central elements. L.E.K. Consulting explained how Abu Dhabi is differentiating in its approach.
In Vivo - September 29, 2026
Emugrobart Down In Obesity But Not Out For SMA
Roche completely drops Chugai-originated antibody for obesity and hands all rights back to Japanese firm, which still sees hope in spinal muscular atrophy and may seek alternative licensees.
Scrip - September 29, 2026
Roche completely drops Chugai-originated antibody for obesity and hands all rights back to Japanese firm, which still sees hope in spinal muscular atrophy and may seek alternative licensees.
Scrip - September 29, 2026
Age-Restricted Sales For Weight Loss, Bodybuilding Supplements Coming To California In January
Council for Responsible Nutrition, contesting a similar law in effect in New York since 2024, and Consumer Healthcare Products Association were quick to criticize the California bill after it was signed into law on Sept. 28 by Gov. Gavin Newsom.
HBW Insight - September 29, 2026
Council for Responsible Nutrition, contesting a similar law in effect in New York since 2024, and Consumer Healthcare Products Association were quick to criticize the California bill after it was signed into law on Sept. 28 by Gov. Gavin Newsom.
HBW Insight - September 29, 2026
TikTok To Brands: Demand More From Creators Or Keep Losing Consumer Trust
TikTok's top brand safety executive tells NAD conference that brands must demand accountability from creators and agencies to reverse advertising's growing trust problem.
HBW Insight - September 29, 2026
TikTok's top brand safety executive tells NAD conference that brands must demand accountability from creators and agencies to reverse advertising's growing trust problem.
HBW Insight - September 29, 2026
Emugrobart Down In Obesity But Not Out For SMA
Roche completely drops Chugai-originated antibody for obesity and hands all rights back to Japanese firm, which still sees hope in spinal muscular atrophy and may seek alternative licensees.
Scrip - September 29, 2026
Roche completely drops Chugai-originated antibody for obesity and hands all rights back to Japanese firm, which still sees hope in spinal muscular atrophy and may seek alternative licensees.
Scrip - September 29, 2026
XVIVO Files Heart Assist Transport PMA, Targets 2027 US Launch
XVIVO has filed a PMA for its Heart Assist Transport, backed by 91.4% one-year survival data from the PRESERVE trial. A 2027 US launch is targeted, with the company also lobbying Congress on Medicare coverage of transplant technology.
Medtech Insight - September 28, 2026
XVIVO has filed a PMA for its Heart Assist Transport, backed by 91.4% one-year survival data from the PRESERVE trial. A 2027 US launch is targeted, with the company also lobbying Congress on Medicare coverage of transplant technology.
Medtech Insight - September 28, 2026
AI-Powered CT Moves From Diagnostic Tool To CAD Care Platform
Global diagnostic imaging major Royal Philips is using partnership approaches to achieve clinical validation of its computed tomography-based integrated care pathway for patients with coronary artery disease.
Medtech Insight - September 28, 2026
Global diagnostic imaging major Royal Philips is using partnership approaches to achieve clinical validation of its computed tomography-based integrated care pathway for patients with coronary artery disease.
Medtech Insight - September 28, 2026
California Firm Wins Breakthrough Designation For Stimulant Use Disorder Device
NET Recovery has received FDA Breakthrough Device Designation for its noninvasive stimulation device as an aid in reducing psychostimulant use in adults with stimulant use disorder. The company is planning a pivotal trial of about 500 patients to support a future FDA marketing submission.
Medtech Insight - September 28, 2026
NET Recovery has received FDA Breakthrough Device Designation for its noninvasive stimulation device as an aid in reducing psychostimulant use in adults with stimulant use disorder. The company is planning a pivotal trial of about 500 patients to support a future FDA marketing submission.
Medtech Insight - September 28, 2026
EASD: Abbott, Dexcom Studies Show CGMs Reduce Mortality; Patient Awareness Still Concern
Abbott and Dexcom release data highlighting the benefits of continuous glucose monitoring as the companies push for broader reimbursement.
Medtech Insight - September 28, 2026
Abbott and Dexcom release data highlighting the benefits of continuous glucose monitoring as the companies push for broader reimbursement.
Medtech Insight - September 28, 2026
Sofinnova Partners Closed $93.4M MD Start IV Fund With Plans To Launch 6 To 8 Start-Ups
Sofinnova Partners closed an oversubscribed (€82m) $93.4m to fund for six to eight medtech companies with a focus on cardiovascular and AI-powered technologies, according to partner Anne Osdoit.
Medtech Insight - September 28, 2026
Sofinnova Partners closed an oversubscribed (€82m) $93.4m to fund for six to eight medtech companies with a focus on cardiovascular and AI-powered technologies, according to partner Anne Osdoit.
Medtech Insight - September 28, 2026
Age-Restricted Sales For Weight Loss, Bodybuilding Supplements Coming To California In January
Council for Responsible Nutrition, contesting a similar law in effect in New York since 2024, and Consumer Healthcare Products Association were quick to criticize the California bill after it was signed into law on Sept. 28 by Gov. Gavin Newsom.
HBW Insight - September 29, 2026
Council for Responsible Nutrition, contesting a similar law in effect in New York since 2024, and Consumer Healthcare Products Association were quick to criticize the California bill after it was signed into law on Sept. 28 by Gov. Gavin Newsom.
HBW Insight - September 29, 2026
TikTok To Brands: Demand More From Creators Or Keep Losing Consumer Trust
TikTok's top brand safety executive tells NAD conference that brands must demand accountability from creators and agencies to reverse advertising's growing trust problem.
HBW Insight - September 29, 2026
TikTok's top brand safety executive tells NAD conference that brands must demand accountability from creators and agencies to reverse advertising's growing trust problem.
HBW Insight - September 29, 2026
Coherus Looks To Sell Off Final Biosimilars Assets
After already divesting its major biosimilars product franchises, Coherus Oncology has initiated a process to sell off the remaining assets related to the legacy business after exiting the biosimilars sector last year.
Generics Bulletin - September 28, 2026
After already divesting its major biosimilars product franchises, Coherus Oncology has initiated a process to sell off the remaining assets related to the legacy business after exiting the biosimilars sector last year.
Generics Bulletin - September 28, 2026
US Industry Sees Opportunity In FDA User-Fee Reauthorizations
The reauthorizations of generic and biosimilar user-fee programs GDUFA and BsUFA bring opportunities and progress for the US off-patent sector, industry association the AAM believes.
Generics Bulletin - September 28, 2026
The reauthorizations of generic and biosimilar user-fee programs GDUFA and BsUFA bring opportunities and progress for the US off-patent sector, industry association the AAM believes.
Generics Bulletin - September 28, 2026
Stada Builds Its Biosimilars Future With Multi-Product SBP Alliance – Including Pembrolizumab
Stada has advanced its biosimilars interests through a partnership with China’s SBP that includes a proposed pembrolizumab rival to Keytruda – as well as up to three additional molecules – in European and CIS markets, with options for the US and Gulf states.
Generics Bulletin - September 28, 2026
Stada has advanced its biosimilars interests through a partnership with China’s SBP that includes a proposed pembrolizumab rival to Keytruda – as well as up to three additional molecules – in European and CIS markets, with options for the US and Gulf states.
Generics Bulletin - September 28, 2026
How Abu Dhabi Is Racing To Set The Gulf’s Fertility Benchmark With Screening And Diagnosis
Abu Dhabi has set a 2030 roadmap to achieve ambitious global reproductive health ecosystem goals. Prevention and preconception health, genetic screening, fertility diagnosis and treatment and IVF are central elements. L.E.K. Consulting explained how Abu Dhabi is differentiating in its approach.
In Vivo - September 29, 2026
Abu Dhabi has set a 2030 roadmap to achieve ambitious global reproductive health ecosystem goals. Prevention and preconception health, genetic screening, fertility diagnosis and treatment and IVF are central elements. L.E.K. Consulting explained how Abu Dhabi is differentiating in its approach.
In Vivo - September 29, 2026